DMAC DiaMedica Therapeutics
- 5.655
- +0.445+8.54%
- 5.655
- 0.0000.00%
DiaMedica Therapeutics News
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
Lake Street Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC)
H.C. Wainwright Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $7 Price Target
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC)
DiaMedica Therapeutics Analyst Ratings
H.C. Wainwright Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Diamedica Therapeutics (DMAC)
Diamedica Therapeutics Initiated at Buy by HC Wainwright & Co.
H.C. Wainwright Initiates DiaMedica Therapeutics(DMAC.US) With Buy Rating, Announces Target Price $7
DiaMedica Therapeutics Analyst Ratings
Oppenheimer Reiterates Outperform on DiaMedica Therapeutics, Maintains $6 Price Target
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Analysis
Price Target
No Data
No Data